Literature DB >> 24391101

New cholesterol guidelines: worth the wait?

Chad Raymond1, Leslie Cho, Michael Rocco, Stanley L Hazen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24391101      PMCID： PMC4019214          DOI： 10.3949/ccjm.81a.13161

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


× No keyword cloud information.
  17 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Statins: new American guidelines for prevention of cardiovascular disease.

Authors:  Paul M Ridker; Nancy R Cook
Journal:  Lancet       Date:  2013-11-20       Impact factor: 79.321

3.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

4.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 May-Jun       Impact factor: 3.443

9.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

10.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors: 
Journal:  Eur Heart J       Date:  2013-02-26       Impact factor: 29.983
View more
  13 in total

Review 1.  Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies.

Authors:  Aditya D Hendrani; Tolulope Adesiyun; Renato Quispe; Steven R Jones; Neil J Stone; Roger S Blumenthal; Seth S Martin
Journal:  World J Cardiol       Date:  2016-02-26

Review 2.  Risks and benefits of statin use in young people with type 1 diabetes.

Authors:  Petter Bjornstad; R Paul Wadwa
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

3.  Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use.

Authors:  Qing Huang; Michael Grabner; Robert J Sanchez; Vincent J Willey; Mark J Cziraky; Swetha R Palli; Thomas P Power
Journal:  Am Health Drug Benefits       Date:  2016-11

4.  Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe.

Authors:  Philip Schwab; Anthony Louder; Yong Li; Rajiv Mallick; Harold Bays
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

5.  Moneyball, gambling, and the new cholesterol guidelines.

Authors:  Rodney A Hayward
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-03-04

6.  Evaluation of LDL goal achievement in statin consumption, south east of Iran.

Authors:  Malihe Aghasizadeh; Saeede Khosravi Bizhaem; Mahin Baniasadi; Mohammad Reza Khazdair; Toba Kazemi
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

7.  Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort.

Authors:  Charlotte Andersson; Danielle Enserro; Martin G Larson; Vanessa Xanthakis; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2015-04-17       Impact factor: 5.501

8.  Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China.

Authors:  Xiao-Jun Ouyang; Yong-Qing Zhang; Ji-Hai Chen; Ting Li; Tian-Tian Lu; Rong-Wen Bian
Journal:  Chin Med J (Engl)       Date:  2018-02-05       Impact factor: 2.628

9.  Cholesterol and prevention of atherosclerotic events: limits of a new frontier.

Authors:  Luís Eduardo Teixeira de Macedo; Faerstein E
Journal:  Rev Saude Publica       Date:  2017-01-12       Impact factor: 2.106

Review 10.  Timing of Administration: For Commonly-Prescribed Medicines in Australia.

Authors:  Gagandeep Kaur; Craig L Phillips; Keith Wong; Andrew J McLachlan; Bandana Saini
Journal:  Pharmaceutics       Date:  2016-04-15       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.